This is old and I have shared this report before.
https://www.bio.org/sites/default/f...6-2015 - BIO, Biomedtracker, Amplion 2016.pdf
The use of biomarkers for patient selection in clinical trials significantly increases likelihood of approval ( by about 3x - covering the transition from Phase I to approval ).
Industry news, page-5
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
-0.090(5.06%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.78 | $1.78 | $1.63 | $449.0K | 263.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2300 | $1.67 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 8176 | 1 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |